. 2021 Mar 31;11(3):885–905. doi: 10.1007/s13555-021-00511-1

Table 4.

Pairwise odds ratio of achieving PASI 90 and 100 response in the long term

PASI 90 response: posterior median (95% CrI)
RIS	1.57 (1.08, 2.28)^a	1.63 (1.12, 2.37)^a	2.25 (1.35, 3.73)^a	2.86 (2.16, 3.82)^a	4.76 (3.64, 6.29)^a	5.48 (3.49, 8.61)^a	9.56 (6.46, 14.28)^a
0.64 (0.44, 0.92)^a	BRO	1.04 (0.71, 1.53)	1.44 (0.87, 2.34)	1.82 (1.36, 2.46)^a	3.03 (2.37, 3.92)^a	3.49 (2.21, 5.52)^a	6.09 (4.07, 9.16)^a
0.61 (0.42, 0.89)^a	0.96 (0.66, 1.42)	GUS	1.38 (0.82, 2.31)	1.76 (1.39, 2.25)^a	2.92 (2.19, 3.94)^a	3.36 (2.56, 4.42)^a	5.88 (4.08, 8.50)^a
0.44 (0.27, 0.74)^a	0.70 (0.43, 1.15)	0.72 (0.43, 1.22)	IXE	1.27 (0.81, 2.02)	2.11 (1.39, 3.26)^a	2.43 (1.37, 4.33)^a	4.24 (2.51, 7.26)^a
0.35 (0.26, 0.46)^a	0.55 (0.41, 0.74)^a	0.57 (0.45, 0.72)^a	0.79 (0.50, 1.23)	SEC	1.66 (1.42, 1.95)^a	1.91 (1.35, 2.71)^a	3.34 (2.54, 4.41)^a
0.21 (0.16, 0.28)^a	0.33 (0.26, 0.42)^a	0.34 (0.25, 0.46)^a	0.47 (0.31, 0.72)^a	0.60 (0.51, 0.71)^a	UST_W	1.15 (0.78, 1.69)	2.01 (1.47, 2.77)^a
0.18 (0.12, 0.29)^a	0.29 (0.18, 0.45)^a	0.30 (0.23, 0.39)^a	0.41 (0.23, 0.73)^a	0.52 (0.37, 0.74)^a	0.87 (0.59, 1.28)	ADA	1.75 (1.12, 2.73)^a
0.10 (0.07, 0.15)^a	0.16 (0.11, 0.25)^a	0.17 (0.12, 0.25)^a	0.24 (0.14, 0.40)^a	0.30 (0.23, 0.39)^a	0.50 (0.36, 0.68)^a	0.57 (0.37, 0.89)^a	ETA

PASI 100 response: posterior median (95% CrI)
RIS	1.50 (1.08, 2.10)^a	1.56 (1.11, 2.19)^a	2.11 (1.32, 3.40)^a	2.66 (2.06, 3.45)^a	4.44 (3.49, 5.68)^a	5.14 (3.29, 8.13)^a	9.40 (6.30, 14.23)^a
0.67 (0.48, 0.93)^a	BRO	1.03 (0.72, 1.48)	1.41 (0.88, 2.24)	1.77 (1.34, 2.34)^a	2.96 (2.35, 3.73)^a	3.42 (2.16, 5.49)^a	6.26 (4.12, 9.60)^a
0.64 (0.46, 0.90)^a	0.97 (0.68, 1.38)	GUS	1.36 (0.83, 2.22)	1.71 (1.37, 2.14)^a	2.86 (2.18, 3.75)^a	3.31 (2.50, 4.42)^a	6.05 (4.15, 8.89)^a
0.47 (0.29, 0.76)^a	0.71 (0.45, 1.14)	0.74 (0.45, 1.20)	IXE	1.26 (0.81, 1.95)	2.10 (1.40, 3.16)^a	2.43 (1.37, 4.34)^a	4.45 (2.60, 7.66)^a
0.38 (0.29, 0.49)^a	0.56 (0.43, 0.75)^a	0.58 (0.47, 0.73)^a	0.79 (0.51, 1.23)	SEC	1.67 (1.43, 1.95)^a	1.93 (1.34, 2.81)^a	3.53 (2.62, 4.84)^a
0.23 (0.18, 0.29)^a	0.34 (0.27, 0.43)^a	0.35 (0.27, 0.46)^a	0.48 (0.32, 0.71)^a	0.60 (0.51, 0.70)^a	UST_W	1.16 (0.78, 1.74)	2.11 (1.50, 3.04)^a
0.19 (0.12, 0.30)^a	0.29 (0.18, 0.46)^a	0.30 (0.23, 0.40)^a	0.41 (0.23, 0.73)^a	0.52 (0.36, 0.74)^a	0.86 (0.57, 1.29)	ADA	1.83 (1.13, 2.95)^a
0.11 (0.07, 0.16)^a	0.16 (0.10, 0.24)^a	0.17 (0.11, 0.24)^a	0.22 (0.13, 0.38)^a	0.28 (0.21, 0.38)^a	0.47 (0.33, 0.67)^a	0.55 (0.34, 0.88)^a	ETA

Values in table are presented as the pairwise odds ratio with the 95% CrI. An odds ratio > 1 indicates that the treatment in that row has a higher probability of achieving PASI response compared with the treatment in that column. An odds ratio < 1 indicates that the treatment in that row has a lower probability of achieving PASI response compared with the treatment in that column

ADA adalimumab, BRO brodalumab, ETA etanercept, GUS guselkumab, IXE ixekizumab, RIS risankizumab, SEC secukinumab, UST_W ustekinumab weight based

^aDenoted that 95% CrI excludes 1